Revolution Medicines' Daraxonrasib Shows Dramatic Survival Benefit in Metastatic Pancreatic Cancer
Revolution Medicines (NASDAQ: RVMD) announced on April 13, 2026 that its oral RAS inhibitor, daraxonrasib, produced a statistically significant overall‑survival advantage in a global Phase...
Read story →